EUVIMEDEUVIMED entdecken
Crossref

Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma

Quan Wang, Xiaoquan Ji, Jing Sun, Aimin Zhang, Jun Jia, Teng Zhang, Wengang Li, Xuezhang Duan

International Journal of Radiation Oncology*Biology*Physics · 2024

DOI: 10.1016/j.ijrobp.2024.03.035 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Radiation Oncology*Biology*Physics, 2024. Verfasst von Quan Wang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Phenylurea Compounds, Liver Neoplasms, Quinolines. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: The aim of this study was to compare the clinical benefit and safety of the triple combination of stereotactic body radiotherapy (SBRT), lenvatinib, and programmed cell death protein 1 (PD-1) inhibitors with the dual combination of SBRT and lenvatinib in patients with unresectable hepatocellular carcinoma (uHCC). METHODS AND MATERIALS: Patients with uHCC who received SBRT in combination with lenvatinib and PD-1 inhibitors or SBRT in combination with lenvatinib alone as first-line treatment from October 2018 to July 2022 were reviewed in this study. The primary endpoints were overall survival (OS) and progression-free survival (PFS). The secondary endpoints were intrahepatic PFS, extrahepatic PFS, and objective remission rate. In addition, safety profiles were assessed by analyzing treatment-related adverse events between the two groups to assess safety profiles. RESULTS: In total, 214 patients with uHCC who received combination therapy were included in this retrospective study. Among them, 146 patients received triple combination therapy of SBRT, lenvatinib, and PD-1 inhibitors (SBRT-L-P group), and 68 patients received dual therapy of SBRT and lenvatinib (SBRT-L group). The median OS times of the 2 groups were 31.2 months and 17.4 months, respectively (P < .001). The median PFS time was significantly longer in the SBRT-L-P group than in the SBRT-L group (15.6 months vs 8.8 months, P < .001). Additionally, the median intrahepatic PFS (17.5 vs 9.9 months, P < .001) and extrahepatic PFS (20.9 vs 11.6 months, P < .001) were significantly longer in the SBRT-L-P group than in the SBRT-L group. The objective remission rate in the SBRT-L-P group was higher than in the SBRT-L group (63.0 vs 39.7%, P = .002). The incidence and severity of treatment-related adverse events in the SBRT-L-P group were comparable to those in the SBRT-L group. CONCLUSION: The use of both lenvatinib and PD-1 inhibitors with SBRT in patients with uHCC was associated with improved overall survival compared with lenvatinib and SBRT alone with a manageable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularPhenylurea CompoundsLiver NeoplasmsQuinolinesRadiosurgeryHumansMaleFemaleAgedMiddle AgedRetrospective StudiesProgrammed Cell Death 1 ReceptorProgression-Free SurvivalCombined Modality TherapyAged, 80 and overAdultImmune Checkpoint Inhibitors

Substanzen

lenvatinibPhenylurea CompoundsQuinolinesProgrammed Cell Death 1 ReceptorImmune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Radiation Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China.
  • Department of Radiation Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China.
  • Department of Radiation Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China. Electronic address: doctor302@163.com.
  • Department of Radiation Oncology, Senior Department of Oncology, the Fifth Medical Center of PLA General Hospital, Beijing, China; The Second School of Clinical Medicine, Southern Medical University, Guangzhou, China. E…

Zitieren

APA

Wang, Q., Ji, X., Sun, J., Zhang, A., Jia, J., Zhang, T., Li, W., & Duan, X. (2024). Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. https://doi.org/10.1016/j.ijrobp.2024.03.035

Vancouver

Wang Q, Ji X, Sun J, Zhang A, Jia J, Zhang T, et al. Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma. International Journal of Radiation Oncology*Biology*Physics. 2024. doi:10.1016/j.ijrobp.2024.03.035

BibTeX
@article{Wang2024,
  author = {Wang, Quan and Ji, Xiaoquan and Sun, Jing and Zhang, Aimin and Jia, Jun and Zhang, Teng and Li, Wengang and Duan, Xuezhang},
  title = {Stereotactic Body Radiotherapy Combined With Lenvatinib With or Without PD-1 Inhibitors as Initial Treatment for Unresectable Hepatocellular Carcinoma},
  journal = {International Journal of Radiation Oncology*Biology*Physics},
  year = {2024},
  doi = {10.1016/j.ijrobp.2024.03.035}
}
Kostenlos starten →